L-cysteine

L-Cysteine: A Comprehensive Reference

1. Identity and Chemical Characterization

Names and Classification

Cysteine (symbol Cys or C) is a semiessential proteinogenic amino acid with the molecular formula HS−CH₂−CH(NH₂)−COOH. L-cysteine is a sulfur-containing amino acid that can be synthesized de novo from methionine and serine in adult humans. L-cysteine is a nutritionally semiessential amino acid and is present mainly in the form of L-cystine in the extracellular space. Its systematic IUPAC name is (R)-2-amino-3-sulfanylpropanoic acid. Its CAS number is 52-90-4. In standard single-letter amino acid notation it is represented by the letter C, and the three-letter abbreviation Cys.

Cysteine is chiral; both D and L forms are found in nature. L-cysteine is a protein monomer in all biota, while D-cysteine acts as a signaling molecule in mammalian nervous systems. Only the L-enantiomer is used in dietary supplements and pharmaceutical preparations.

Cysteine is named after its discovery in urine, which comes from the urinary bladder or cyst, from Greek κύστις (kýstis), meaning "bladder."

Physical and Chemical Properties

L-cysteine monohydrochloride is a white, odorless crystalline powder with a characteristic acid, slightly sweetish taste; it is soluble in water and alcohol and has a melting point of 175°C. The thiol side chain in cysteine enables the formation of disulfide bonds, and often participates in enzymatic reactions as a nucleophile. The thiol is susceptible to oxidation, yielding the disulfide derivative cystine, which serves an important structural role in many proteins.

Common Forms and Preparations

Dietary supplements and pharmaceutical preparations containing L-cysteine are available in several chemical forms:

• Free L-cysteine: The unmodified amino acid, used in some oral supplements. Relatively unstable due to ready oxidation of the free thiol group.
• L-cysteine hydrochloride (monohydrate): The most commercially common salt form, stabilized by the addition of hydrochloric acid.
• L-cystine: This is the oxidized dimer form most relevant to keratin biology, since disulfide bonds between cysteine residues create cystine cross-links in structural proteins. L-cystine is more stable than free L-cysteine and is the form used in many hair-targeted supplements and in the approved oral combination Pantovigar.
• N-acetyl-L-cysteine (NAC): NAC is L-cysteine with an acetyl group attached to the amino nitrogen. This chemical modification significantly improves stability and protects the molecule from degradation during digestion. Once absorbed, NAC is deacetylated in the body to release free L-cysteine, which can then feed glutathione synthesis. NAC's oral bioavailability is still low (approximately 4–10% after first-pass metabolism), but it is the most extensively studied form in clinical research and has an established track record as a pharmaceutical agent for acetaminophen overdose, chronic obstructive pulmonary disease, and mucolytic therapy.
• Prodrugs: Compounds such as L-2-oxothiazolidine-4-carboxylate (Procysteine) are inactive until metabolized intracellularly, at which point they release free cysteine and stimulate glutathione synthesis. Procysteine is a prodrug of cysteine that is inert until metabolized to cysteine intracellularly, thus stimulating glutathione synthesis.

2. Natural Sources

Dietary Sources

L-cysteine is a semi-essential amino acid, abundant in many foods such as beef liver, crab cakes, lima beans, and some mushrooms. High-protein foods in general — including poultry, eggs, dairy products, and legumes — supply meaningful quantities of cysteine as part of their overall protein content.

In humans and animals, L-cysteine is primarily found in the hair, nails, and skin, especially in collagen.

Endogenous Biosynthesis

Cysteine is a semi-essential amino acid that can be obtained both from the diet and synthesized endogenously via the reverse transsulfuration pathway from methionine. Cysteine is generated by the enzyme cystathionase/cystathionine γ-lyase (CSE) from cystathionine, which in turn is generated by the condensation of homocysteine and serine by cystathionine β-synthase (CBS).

L-cysteine has been classified as conditionally essential in some cases. For example, it can be conditionally essential in preterm infants due to biochemical immaturity of the enzyme cystathionase that is involved in L-cysteine synthesis.

Commercial and Manufacturing Sources

One biological source is the extraction of keratin from human hair by use of hydrochloric acid and water. After several steps, keratin is hydrolyzed and purified into L-cystine, which is then dissolved in a hydrochloric acid solution and converted by electrolysis to L-cysteine monohydrochloride.

L-cysteine can be derived from animal and even human sources such as goose and duck feathers, human hair, swine bristles, and hooves; there is also a well-established fermentation process using plant starch as raw material.

A more sustainable fermentation process for producing vegan L-cysteine and L-cystine has been introduced, using plant-based raw materials such as corn and inorganic trace elements. This method is more sustainable compared to the chemical extraction that uses large amounts of acid.

3. Historical and Traditional Use

Pre-Scientific Traditions

Foods rich in L-cysteine have been known for their health benefits since the Middle Ages. Chicken macerates containing it were often used to treat asthma. Drugs based on derivatives are still used today for asthma and other chronic obstructive pulmonary diseases (COPD).

In traditional medicine, cysteine-containing foods such as eggs and meat were recognized for their nourishing effects on skin, hair, and immune health. These uses were associated with the foods themselves rather than with any isolated compound; the specific role of cysteine within them was not understood.

Early Scientific Identification

L-cystine was first recognized in the 19th century as a component of protein structures due to its involvement in sulfur-containing disulfide bonds. The earliest publications focusing on L-cysteine can be traced back to the first third of the 20th century. In the early 20th century, research began to reveal its importance in protein structure and its ability to influence enzyme activity in the body.

The use of L-cysteine as a specific supplement for detoxification or respiratory health has become more common in recent decades as research into antioxidant defense and glutathione synthesis advanced. The number of publications about the use of L-cysteine for these purposes has increased significantly during the last two decades, an increase closely related to the rise of nutraceutical industries and personalized medicine.

4. Key Constituents and Active Compounds

The Thiol (Sulfhydryl) Group

The defining feature of L-cysteine is its free thiol (–SH) group attached to the side chain. This thiol side chain enables the formation of disulfide bonds and often participates in enzymatic reactions as a nucleophile. The thiol group is the structural basis for L-cysteine's capacity to participate in redox chemistry, protein folding, enzyme catalysis, and the biosynthesis of other sulfur-containing molecules.

Role as a Precursor to Glutathione (GSH)

Intracellular L-cysteine plays an important role in cellular homeostasis as a precursor for protein synthesis, and for production of glutathione (GSH), hydrogen sulfide (H₂S), and taurine.

Glutathione is present in all mammalian tissues as the most abundant non-protein thiol that defends against oxidative stress. GSH is also a key determinant of redox signaling, vital in detoxification of xenobiotics, and regulates cell proliferation, apoptosis, immune function, and fibrogenesis.

Biosynthesis of GSH occurs in the cytosol in a tightly regulated manner. Key determinants of GSH synthesis are the availability of the sulfur amino acid precursor cysteine, and the activity of the rate-limiting enzyme glutamate cysteine ligase (GCL), which is composed of a catalytic (GCLC) and a modifier (GCLM) subunit. The second enzyme of GSH synthesis is GSH synthetase (GS).

The tripeptide glutathione is synthesized in a two-step process in which cysteine and glutamate are linked by glutamate cysteine ligase to form gamma-glutamylcysteine, which is then linked to glycine by glutathione synthase.

Approximately 50% of the cysteine generated by the transsulfuration pathway is utilized for GSH biosynthesis in hepatic cells.

Role as a Precursor to Hydrogen Sulfide (H₂S)

Cysteine is also the precursor of the gaseous signaling molecule hydrogen sulfide (H₂S) and other sulfur metabolites. There are two pathways for the catabolism of cysteine leading to sulfate, taurine, and thiosulfate as terminal products. The oxidative pathway produces taurine and sulfate, while the H₂S pathway involves different enzymatic reactions leading to the formation and clearance of H₂S, an important signaling molecule in mammals, resulting in thiosulfate and sulfate.

Sulfhydration, the most recently discovered physiological modification of cysteine, plays diverse roles in physiology ranging from response to inflammation to neuroprotection. Dysregulated cysteine and hydrogen sulfide metabolism is frequently encountered in several neurodegenerative disorders.

Role as a Precursor to Taurine

Cysteine is converted to the sulfur-containing molecule taurine by the action of the enzyme cysteine dioxygenase (CDO) to form cysteinesulfinic acid, which can then be decarboxylated to hypotaurine by cysteinesulfinic acid decarboxylase, and the hypotaurine generated is then oxidized to taurine.

Cysteine has further important effects on glutathione and taurine production in the liver, and thereby on oxidative stress, lipid metabolism, and inflammation.

Role as a Precursor to Coenzyme A and Other Sulfur Metabolites

Once generated, cysteine is consumed by various metabolic pathways such as protein synthesis and generation of sulfur-containing molecules such as glutathione, taurine, lanthionine, coenzyme A, and the gasotransmitter hydrogen sulfide (H₂S). L-cysteine plays a key role in sulfur metabolism in all organisms and is used in the synthesis of proteins, glutathione, biotin, lipoic acid, methionine, and other sulfur-containing metabolites. Moreover, L-cysteine serves as a precursor for the biosynthesis of coenzyme A.

Structural Role in Proteins

The thiol group of cysteine is susceptible to oxidation to give the disulfide derivative cystine, which serves an important structural role in many proteins. In vitro research has shown that L-cystine (the oxidized dimer of cysteine) promotes keratin expression in human hair follicular keratinocytes through de novo protein synthesis, while also providing protection against endogenous oxidative stress.

5. Mechanisms of Action

Antioxidant Defense via GSH Upregulation

The primary mechanism by which L-cysteine supplementation is proposed to exert its effects is through increasing intracellular glutathione levels. Extracellular L-cystine crosses the plasma membrane with the help of a transport system, and is reduced to L-cysteine within cells by thioredoxin and reduced glutathione. GSH plays critical roles in protecting cells from oxidative damage and the toxicity of xenobiotic electrophiles, and maintaining redox homeostasis. Because cysteine availability is the rate-limiting step for GSH synthesis, supplemental L-cysteine can raise intracellular GSH when dietary cysteine is insufficient.

Mucolytic Action

NAC's well-established mucolytic action helps break disulfide bonds in thick mucus, improving fluidity. This property is used clinically for airway hygiene, although that effect relates to NAC's chemistry rather than to free L-cysteine per se, illustrating how the cysteine family supports respiratory care.

Modulation of Skin Pigmentation

Melanin synthesis starts from a common reaction in which tyrosine or dihydroxyphenylalanine (DOPA) is oxidized by tyrosinase to produce dopaquinone (DQ). DQ is spontaneously converted to leukodopachrome and then to dopachrome, entering the eumelanin synthesis pathway. When DQ reacts with cysteine, cysteinyl dopa is generated, which enters the pheomelanin synthesis pathway. Thiol compounds can therefore influence the relative synthesis of eumelanin and pheomelanin. In addition, thiol compounds can inhibit enzymatic activity by binding to copper ions at the active site of tyrosinase and act as antioxidants scavenging reactive oxygen species and free radicals, thereby inhibiting overall melanin synthesis.

Protein and Keratin Synthesis

L-cysteine performs a variety of metabolic functions, including involvement in growth and protein synthesis, and it is a precursor for glutathione, an important intracellular antioxidant. Cysteine residues are exceptionally abundant in keratin and collagen, the principal structural proteins of hair, nails, and skin.

Transsulfuration and Redox Signaling

Synthesis of cysteine as a product of the transsulfuration pathway can be viewed as part of methionine or homocysteine degradation, with cysteine being the vehicle for sulfur conversion to end products that can be excreted in the urine. Transsulfuration is regulated by stimulation of cystathionine β-synthase and inhibition of methylene tetrahydrofolate reductase in response to changes in the level of S-adenosylmethionine, promoting homocysteine degradation when methionine availability is high.

6. Scientific Evidence by Area of Use

Overview of the Evidence Base

A systematic review published in Molecules (2018) used three databases (PubMed, Scopus, and Web of Science) to compile documents published between 1950 and 2017, ultimately selecting 60,885 primary publications to compile information about the use of L-cysteine in medicine and nutritional therapies. In total, 92% of the identified studies were descriptions of the physicochemical properties of L-cysteine or its biological roles; 8,304 (6.54%) were systematic reviews and 1,638 (1.29%) were clinical trials. The lack of accurate information and studies based on clinical trials hampers consensus among authors; the debate about the role and effectiveness of supplements and drugs containing L-cysteine is still open.

Hair Growth and Hair Loss

Clinical studies have confirmed that hair-growth-promoting oral drug combinations are beneficial for the treatment of diffuse telogen effluvium, which is characterized by the excessive loss of telogen club hairs, though data elucidating the mode of action of such combinations are limited. A minimal growth culture system was used to mimic the reduced activity of human hair follicular keratinocytes (HHFKs); the effect of four core compounds (L-cystine, thiamine, calcium D-pantothenate, and folic acid) of the marketed oral combination Pantovigar®, approved for the treatment of diffuse hair loss, was examined by comparing HHFKs cultured with or without the compounds.

A 2023 randomized controlled trial found that a supplement containing L-cystine, iron, selenium, and marine hydrolyzed collagen improved hair parameters in subjects with androgenetic alopecia and telogen effluvium.

Research has demonstrated that cysteine supplementation can counteract the negative effects of iron deficiency on keratin expression in keratinocytes, likely by upregulating transferrin receptor and ferritin expression.

Most clinical hair loss trials use L-cystine in combination with other compounds (vitamins, minerals), making it difficult to isolate the specific contribution of cysteine. Evidence for isolated free L-cysteine in hair loss remains limited.

Skin Aging and Appearance

A randomized, double-blind, placebo-controlled study administered a feather keratin hydrolysate (FKH), characterized by a high content of free L-amino acids including L-cysteine, to adult women showing physiological aging signs, with participants randomly assigned to receive daily dosages of 500 or 1000 mg of FKH or placebo for 90 days. Parameters of skin roughness, wrinkle features, deep skin moisturization, skin elasticity, skin thickness, and nail hardness were evaluated. Both FKH treatments showed significant improvement of all parameters compared to day 0 and to placebo (with an exception for fiber anisotropy and fiber density), bolstered by the results of a self-assessment questionnaire showing an overall set of positive answers for both treatments compared to placebo. Oral supplementation of FKH for 90 days was associated with improvement in the appearance of facial skin, hair, and nails. This study used a complex amino acid mixture rather than pure L-cysteine, limiting direct attribution.

Skin Pigmentation and Lightening

A 12-week randomized, double-blind, parallel-group, benchmark- and placebo-controlled trial investigated the skin lightening and anti-dark spot effects of oral supplementation with L-cystine associated with L-glutathione. It enrolled 124 Asian female subjects, randomly allocated into four equal groups receiving either 500 mg L-cystine and 250 mg L-glutathione, 250 mg reduced L-glutathione alone, 500 mg L-cystine alone, or a placebo, daily. The results showed that the combination of L-cysteine and L-glutathione lightened the skin on the cheeks and the lower forearm; no effect was observed with the placebo.

Cysteine-containing dipeptides such as γ-Glu-Cys and Cys-Gly can serve as additional sources of cysteine and glutamate/glycine to enhance intracellular GSH production when GSH is depleted due to UV-B–induced oxidative stress. The suppression of UV-induced pigmentation can be explained by the multiple inhibitory mechanisms of melanin production by GSH, including disruption of the intracellular trafficking of tyrosinase to melanosomes, suppression of tyrosinase activity, and inducing the production of pheomelanin instead of eumelanin.

Several clinical trials have been conducted on the skin lightening effects of glutathione, its oxidized form, and cysteamine, and evidence for their efficacy has been partially established. Clinical trials on cysteine, N-acetylcysteine, and cystine specifically are still insufficient. The skin-lightening evidence base is therefore classified as preliminary.

Antioxidant Status and Metabolic Health

Diabetes is associated with lower levels of glutathione and 25(OH) vitamin D. A study examined the hypothesis that upregulation of GSH would also upregulate blood levels of vitamin D binding protein (VDBP) and 25(OH) vitamin D in type 2 diabetic rats. L-cysteine supplementation was used to upregulate GSH status in a hepatocyte cell culture model and in vivo using Zucker diabetic fatty (ZDF) rats. Results showed that L-cysteine supplementation upregulates both protein and mRNA expression of VDBP and vitamin D receptor (VDR) and GSH status in hepatocytes exposed to high glucose. This is preclinical evidence; direct human trials assessing the same endpoints are limited.

Circulating and tissue levels of glutathione decrease with age and in chronic diseases such as diabetes. GSH is a cofactor of many enzymes, a potent antioxidant, and plays an important role as a scavenger of toxic oxygen radicals, which helps to maintain normal cell functions.

Smoking Cessation

Preliminary clinical studies have shown that the use of a slow-release tablet containing 3 mg of L-cysteine with each cigarette for 6 months does not increase the chances of quitting smoking compared with a placebo. A more qualitative study conducted by the same research group showed that the use of this tablet increases the chances of quitting smoking by approximately 51% compared with a placebo. The evidence for L-cysteine in smoking cessation is therefore mixed and limited to small preliminary studies.

Parenteral Nutrition in Preterm Infants

Due to their gastrointestinal immaturity or the severity of their pathology, many neonates require parenteral nutrition (PN). An amino acid solution is an important part of PN. Cysteine is a key amino acid for protein and taurine synthesis, as well as for glutathione synthesis, which is a cornerstone of antioxidant defenses. Many studies suggest that cysteine is a conditionally essential amino acid in preterm infants due to limitations in their capacity for cysteine synthesis from methionine and the immaturity of their cellular cysteine uptake.

Nitrogen retention was significantly increased by cysteine supplementation across four trials (WMD 31.8 mg/kg/day, 95% confidence interval +8.2, +55.4, n = 95, including 73 preterm infants). Plasma levels of cysteine were significantly increased by cysteine supplementation. Six trials fulfilled entry criteria, with the majority of patients being preterm. Five small trials evaluated short-term cysteine supplementation of cysteine-free PN.

Available evidence from randomized controlled trials (RCTs) shows that routine short-term cysteine chloride supplementation of cysteine-free PN in preterm infants improves nitrogen balance. However, there is insufficient evidence to assess the risks of cysteine supplementation, especially regarding metabolic acidosis, which has been reported during the first two weeks of cysteine chloride administration. Available evidence from a large RCT does not support routine N-acetylcysteine supplementation of cysteine-containing PN in extremely low birth weight infants.

Clinical recommendations from Children's Hospital of Philadelphia specify 40 mg/kg/day cysteine per 1 g/kg/day of amino acids, used when needed to enhance calcium and phosphorus solubility in PN formulations.

Neurodegenerative and Neurological Applications

Dysregulated cysteine and hydrogen sulfide metabolism is frequently encountered in several neurodegenerative disorders. In the mouse brain, the activity of the transsulfuration pathway is lower compared to the liver, but the flux can be increased by oxidative stress. Research in this area remains largely preclinical (animal models and cell lines). Robust human clinical trials examining L-cysteine supplementation specifically for neurological outcomes are not yet available in the peer-reviewed literature.

Detoxification

L-cysteine is used as a starting material for producing pharmaceutical active ingredients, in particular N-acetylcysteine and S-carboxymethylcysteine. NAC, the most widely studied cysteine derivative, is established as a standard clinical treatment for acetaminophen (paracetamol) overdose — an application based on cysteine's role in GSH replenishment in the liver — though this is a pharmaceutical application of NAC, not of free oral L-cysteine supplementation. The use of free oral L-cysteine for detoxification in healthy adults lacks strong clinical trial support.

7. Body Systems and Health Areas

• Integumentary system (skin, hair, nails): In humans and animals, L-cysteine is primarily found in the hair, nails, and skin, especially in collagen. Cysteine's contribution to keratin and collagen cross-linking makes it integral to the structural integrity of these tissues.
• Antioxidant / Redox system: As the rate-limiting precursor of glutathione, L-cysteine is central to cellular oxidative defense throughout the body.
• Hepatic system: Hepatocytes supply GSH found in the plasma, which is used as a source of cysteine for GSH synthesis in other cells. The liver is the principal site of L-cysteine catabolism and GSH production.
• Respiratory system: NAC (the acetylated derivative) is a pharmacologically recognized mucolytic; cysteine's thiol chemistry underlies the disruption of mucus disulfide bonds.
• Nervous system: Cysteine is the precursor for several sulfur-containing molecules including the gaseous signaling molecule hydrogen sulfide, taurine, coenzyme A, and biotin, all of which have neurological relevance.
• Neonatal / Pediatric nutrition: Conditionally essential status in preterm infants makes L-cysteine a specific nutritional concern in neonatal intensive care.
• Immune system: GSH supports immune cell proliferation and function; by maintaining GSH levels, adequate cysteine supply is considered immunologically important.

8. Dosage Forms and Dosages Reported in Studies

The following dosages appear in identified clinical and research literature:

• Oral capsules / tablets — adult supplementation: Daily dosages of 500 mg or 1000 mg of a feather keratin hydrolysate (high-content free amino acid mixture including L-cysteine) were administered for 90 days in a randomized controlled trial evaluating skin, hair, and nail outcomes.
• Oral — smoking cessation study: A slow-release tablet containing 3 mg of L-cysteine per cigarette smoked was evaluated in preliminary clinical studies for smoking cessation over 6 months.
• Oral — skin pigmentation: 500 mg L-cystine (the oxidized dimer) with or without 250 mg L-glutathione per day was administered in a 12-week randomized, double-blind trial assessing skin lightening in 124 subjects.
• Parenteral (intravenous/PN) — neonates: Recommendations of 40 mg/kg/day cysteine per 1 g/kg/day of amino acids have been specified for parenteral nutrition in preterm infants.
• Intravenous — acute toxicity studies (animal): In a neonatal rat toxicity study, mortality at 7 days after single intravenous dosages of L-cysteine at 1.52 or 1.14 g/kg was 80% and 50%, respectively. These are preclinical toxicity data and not human therapeutic doses.

No standardized upper tolerable limit for daily oral L-cysteine supplementation in healthy adults has been established by major regulatory authorities (NIH ODS, EFSA) as of the available literature. Widely cited figures in the clinical research literature for NAC (the most studied cysteine prodrug form) generally range from 600 mg to 2400 mg per day in divided oral doses, depending on indication, but these pertain to the NAC form, not free L-cysteine.

9. Safety Considerations and Interactions

General Oral Safety

L-cysteine is generally classified as a non-essential or "semi-essential" amino acid because it can be synthesized in small amounts by the human body. However, some adults can still benefit from L-cysteine supplementation. Oral L-cysteine as found in food is consumed safely as part of normal dietary protein.

Toxicity at High Doses — Preclinical Evidence

Two 4-week repeated-dose toxicity studies were conducted to evaluate the potential toxicity of L-cysteine and D-cysteine. In one study, three groups of 6 male rats were each administered L-cysteine once daily by gavage at doses of 500, 1,000, or 2,000 mg/kg/day for 28 consecutive days, compared against a methylcellulose vehicle control. Toxicological observations showed that the L-cysteine-treated groups exhibited renal injuries such as basophilic tubules with eosinophilic material in the lumen, with increased numbers of basophilic tubules in all treated groups. In the 1,000 or 2,000 mg/kg/day-treated groups, salivation and necropsy findings indicative of focal erosion in the stomach mucosa were found, and increases in reticulocyte counts were observed in the 2,000 mg/kg/day-treated group. The no-observed-adverse-effect levels (NOAELs) were estimated to be less than 500 mg/kg/day for L-cysteine under these study conditions. These are rodent studies and cannot be directly extrapolated to human dosing.

Excess Cysteine and Toxicity

Excess cysteine is toxic and is catabolized by multiple alternative desulfuration reactions catalyzed by CBS and/or CGL that generate either hydrogen sulfide or sulfane sulfur, both of which are subsequently oxidized to sulfate. Sulfite is a common intermediate in both catabolic pathways, and is considered cytotoxic and produces neurotoxic S-sulfonates.

Metabolic Acidosis in Neonates

There is insufficient evidence to assess the risks of cysteine supplementation in preterm infants, especially regarding metabolic acidosis, which has been reported during the first two weeks of cysteine chloride administration. Addition of amino acids, especially with the addition of cysteine hydrochloride, renders parenteral nutrition solutions acidic, which is a clinically relevant consideration in neonatal PN.

Conditional Essentiality and Developmental Considerations

Many studies suggest that cysteine is a conditionally essential amino acid in preterm infants due to limitations in their capacity for cysteine synthesis from methionine and the immaturity of their cellular cysteine uptake. This is a distinct population-specific safety and efficacy consideration.

Instability of Supplemental Preparations

Cysteine supplementation is limited by associated toxicity and product instability. The free thiol group of L-cysteine makes it prone to oxidation in solution or at high temperatures, reducing effective potency over shelf life. This is a particular concern for parenteral preparations.

Evidence Gaps and Limitations

The lack of accurate information and studies based on clinical trials hampers consensus among authors, and the debate about the role and effectiveness of supplements and drugs containing L-cysteine is still open. Clinical trials on cysteine, N-acetylcysteine, and cystine are still insufficient across several proposed indications, including skin lightening, hair growth, and metabolic health. Much of what is cited in commercial contexts as "L-cysteine benefits" is actually evidence derived from studies of NAC or combined multi-ingredient preparations, and the effects cannot be straightforwardly attributed to free L-cysteine alone.

References

• Rezaei Zadeh Rukerd M, et al. "L-Cysteine metabolism and its nutritional implications." PubMed, 2015.
• Clemente Plaza N, Reig García-Galbis M, Martínez-Espinosa RM. "Effects of the Usage of l-Cysteine (l-Cys) on Human Health." Molecules, 23(3):575, 2018. PMC6017824.
• Clemente Plaza N, et al. "Effects of the Usage of l-Cysteine (l-Cys) on Human Health." MDPI Molecules, 2018.
• Lu SC. "Glutathione Synthesis." Biochimica et Biophysica Acta, PMC3549305.
• Wu G, et al. "Glutathione: Overview of its protective roles, measurement, and biosynthesis." PMC2696075.
• Patel D, et al. "L-cysteine supplementation upregulates glutathione (GSH) and vitamin D binding protein (VDBP) in hepatocytes cultured in high glucose and in vivo in liver." PMC4876732.
• Cummings NE, et al. "Cysteine and hydrogen sulphide in the regulation of metabolism: insights from genetics and pharmacology." PMC4832394.
• Chiku T, et al. "Homeostatic impact of sulfite and hydrogen sulfide on cysteine catabolism." PMC6346071.
• Sbodio JI, Snyder SH, Paul BD. "Regulators of the transsulfuration pathway." PMC6346075.
• Bhatt M, et al. "Cysteine metabolism in neuronal redox homeostasis." PMC5912966.
• Stipanuk MH. "Dealing with methionine/homocysteine sulfur: cysteine metabolism to taurine and inorganic sulfur." PMC2901774.
• Exploring the Antioxidant Roles of Cysteine and Selenocysteine in Cellular Aging and Redox Regulation. PMC12384178.
• Challenges and Advances in the Bioproduction of L-Cysteine. PMC10821248.
• Riegel K, et al. "L-Cystine-Containing Hair-Growth Formulation Supports Protection, Viability, and Proliferation of Keratinocytes." PubMed, 2020.
• Soghier LM, Brion LP. "Cysteine, cystine or N-acetylcysteine supplementation in parenterally fed neonates." PMC (Cochrane Review), 2006. PMC8855743.
• Parenteral Cysteine Supplementation in Preterm Infants: One Size Does Not Fit All. PMC10813382.
• Comparisons of l-cysteine and d-cysteine toxicity in 4-week repeated-dose toxicity studies of rats. PubMed, 2017.
• White RD, et al. "Toxicity evaluations of L-cysteine and Procysteine given once intravenously to neonatal rats." PubMed, 1993.
• Duperray J, et al. "The effects of the oral supplementation of L-Cystine associated with reduced L-Glutathione on human skin pigmentation." Journal of Cosmetic Dermatology, 2022.
• Oral administration of cysteine peptides attenuates UV-B-induced skin erythema and pigmentation in humans. Scientific Reports, 2024.
• Boo YC. "Metabolic Basis and Clinical Evidence for Skin Lightening Effects of Thiol Compounds." PMC8944565.
• Tursi et al. "The Effects of an Oral Supplementation of a Natural Keratin Hydrolysate on Skin Aging." PMC11743286.
• Wikipedia. "Cysteine."
• BAKERpedia. "L-Cysteine: Reducing Agent, Baking Ingredients."
• Altered hepatic sulfur metabolism in cystathionine β-synthase-deficient homocystinuria. PMC5395733.
• Children's Hospital of Philadelphia. "Preterm Nutrition Parenteral Nutrition Consensus Statement." 2024.